| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Lotemax is owned by Bausch And Lomb.
Lotemax contains Loteprednol Etabonate.
Lotemax has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Lotemax are:
- US4996335*PED
- US5540930
- US5747061
- US5540930*PED
- US5747061*PED
Lotemax was authorised for market use on 09 March, 1998.
Lotemax is available in suspension/drops;ophthalmic dosage forms.
Lotemax can be used as lotemax ophthalmic suspension is indicated for the treatment of steroid responsive conditions of the palpebral bulbar conjunctiva, cornea and anterior segment of the globe..
The generics of Lotemax are possible to be released after 25 April, 2014.
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 09 March, 1998
Treatment: Lotemax ophthalmic suspension is indicated for the treatment of steroid responsive conditions of the palpebral bulbar conjunctiva, cornea and anterior segment of the globe.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5540930 | PHARMOS | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
Lotemax is owned by Pharmos.
Lotemax contains Loteprednol Etabonate.
Lotemax has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lotemax are:
- US5540930
Lotemax was authorised for market use on 09 March, 1998.
Lotemax is available in suspension/drops;ophthalmic dosage forms.
The generics of Lotemax are possible to be released after 25 October, 2013.
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 09 March, 1998
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5800807 | BAUSCH AND LOMB INC | Ophthalmic compositions including glycerin and propylene glycol |
Jan, 2017
(7 years ago) | |
Lotemax is owned by Bausch And Lomb Inc.
Lotemax contains Loteprednol Etabonate.
Lotemax has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lotemax are:
- US5800807
Lotemax was authorised for market use on 28 September, 2012.
Lotemax is available in gel;ophthalmic dosage forms.
The generics of Lotemax are possible to be released after 20 July, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-229) | Jul 20, 2021 |
| New Dosage Form(NDF) | Sep 28, 2015 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 28 September, 2012
Treatment: NA
Dosage: GEL;OPHTHALMIC
LOTEMAX family patents